Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 50, Issue 1, pp 25–32 | Cite as

Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function

  • Masataka Ikeda
  • Hiroshi Furukawa
  • Hiroshi Imamura
  • Jyunzo Shimizu
  • Hideyuki Ishida
  • Seizo Masutani
  • Masayuki Tatsuta
  • Takatoshi Kawasaki
  • Takashi Satomi
Original Article

Heading

Abstract

Purpose. S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). As 50% of CDHP is excreted in the urine, renal dysfunction may directly affect the DPD inhibitory effect and lead to increased 5-fluorouracil (5-FU) concentrations. We sought to determine the influence of impaired renal function on the pharmacokinetics of S-1 in an animal model and in patients with gastric cancer.

Methods. An experimental renal failure model induced by cisplatin was developed in rabbits, and plasma concentrations of FT, 5-FU, CDHP and Oxo were determined after S-1 injection. Four patients with various degrees of renal impairment with unresectable gastric cancer were recruited to the study, and the pharmacokinetics in these four patients were analyzed following single and consecutive S-1 administrations.

Results. In experimental renal failure, plasma clearance of CDHP and 5-FU was retarded corresponding to the degree of renal impairment and there was a close correlation between creatinine clearance (CLcr) and plasma CDHP and 5-FU clearance. In the single administration study, half standard dose was used in three patients (CLcr ≥50 ml/min) and one-third in the other (CLcr <50 ml/min). In patients with CLcr more than 75 ml/min, Cmax, Tmax, AUC(0–∞), and T1/2 of 5-FU and CDHP were not different between single and consecutive administrations. In contrast, in patients with mild and moderate renal dysfunction (CLcr 55 and 36 ml/min, respectively), the T1/2 values of CDHP with consecutive administrations (7.6 and 15.3 h, respectively) were longer than the values with single administration (4.6 and 8.2 h, respectively). The T1/2 of 5-FU was 5.7 h with single administration and 8.5 h with consecutive administration in patients with moderate renal impairment. The AUC(0–∞) of 5-FU with consecutive administrations (3089.7 ng·h/ml) was far greater than with single administration (430.4 ng·h/ml). There was also a strong correlation between CLcr and plasma CDHP clearance. Based on the pharmacokinetics following multiple consecutive administrations, S-1 administration resulted in no severe adverse reactions in any of the four patients.

Conclusions. CDHP clearance was prolonged in the presence of renal impairment, leading to a delayed T1/2, and high AUC of 5-FU. These findings demonstrate that administration of S-1 to patients with impaired renal function may need individualized dosing and pharmacokinetic monitoring.

Gastric cancer S-1 CDHP (5-chloro-2, 4-dihydroxypyridine) 5-FU Renal dysfunction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag 2002

Authors and Affiliations

  • Masataka Ikeda
    • 1
  • Hiroshi Furukawa
    • 2
  • Hiroshi Imamura
    • 2
  • Jyunzo Shimizu
    • 2
  • Hideyuki Ishida
    • 2
  • Seizo Masutani
    • 2
  • Masayuki Tatsuta
    • 2
  • Takatoshi Kawasaki
    • 2
  • Takashi Satomi
    • 2
  1. 1.Department of Surgery and Clinical Oncology (E2), Graduate School of Medicine, Osaka University, 2-2 Yamadaoka Suita, Osaka 565-0871, Japan
  2. 2.Department of Surgery, Sakai Municipal Hospital, Osaka 590-0064, Japan

Personalised recommendations